Lebers congential amaurosis gene therapy (University Medical Center St Radboud)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLebers congential amaurosis gene therapy (University Medical Center St Radboud)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionCentrosomal protein of 290 kDa modulators
TargetsCentrosomal protein of 290 kDa
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDepartment Of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDepartment Of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
Active IndicationsN/A
Inactive IndicationsLeber Congenital Amaurosis

Other Information

ATC CodeN/A
Related LinksN/A